Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Guggenheim Analyst Says

Key Points

• Guggenheim analysts raised their price target for Dianthus Therapeutics from $92.00 to $100.00, indicating a potential upside of 214.47% from the previous close, with a current "buy" rating.
• Other analysts, such as Wedbush and Robert W. Baird, also issued positive outlooks, raising their target prices significantly, with a general consensus showing an average rating of "Buy" and a price target of $59.50.
• Dianthus Therapeutics recently reported a quarterly loss of ($0.88) EPS, missing estimates, and had a negative net margin of 2,364.56%, suggesting ongoing financial challenges despite optimistic analyst ratings.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) had its price target raised by stock analysts at Guggenheim from $92.00 to $100.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's price objective indicates a potential upside of 214.47% from the company's previous close.

Several other equities analysts have also recently weighed in on the company. Wedbush lifted their target price on Dianthus Therapeutics from $34.00 to $42.00 and gave the company an "outperform" rating in a research note on Thursday, August 21st. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday. William Blair assumed coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an "outperform" rating for the company. Finally, Robert W. Baird boosted their price target on Dianthus Therapeutics from $50.00 to $67.00 and gave the company an "outperform" rating in a research note on Tuesday. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $59.50.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $31.80 on Tuesday. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $32.80. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -9.78 and a beta of 1.46. The stock's fifty day moving average is $21.54 and its 200-day moving average is $20.09.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. Analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. bought a new position in Dianthus Therapeutics during the second quarter worth about $27,000. US Bancorp DE lifted its stake in Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after acquiring an additional 1,510 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Dianthus Therapeutics during the 4th quarter worth approximately $59,000. GAMMA Investing LLC lifted its stake in Dianthus Therapeutics by 3,030.6% in the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after acquiring an additional 3,758 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock valued at $80,000 after acquiring an additional 3,317 shares during the period. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.